Drugs - Real World Outcomes (Feb 2020)

Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study

  • Nestor Szerman,
  • Ignacio Basurte-Villamor,
  • Pablo Vega,
  • Jose Martinez-Raga,
  • Carlos Parro-Torres,
  • Julia Cambra Almerge,
  • Lara Grau-López,
  • Mario De Matteis,
  • Francisco Arias

DOI
https://doi.org/10.1007/s40801-020-00184-w
Journal volume & issue
Vol. 7, no. 1
pp. 85 – 85

Abstract

Read online

A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone [29].